NNVC.OB: NanoViricides, Inc. Twitter on Stock

NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Initial Clinical Trials of Its First Drug Candidate

Business Wire (Wed, 7:00AM)
NanoViricides, Inc. Brings in Experienced Executive as Interim CFO

Business Wire (May 13, 2013)
NanoViricides to Present at the 2013 BIO International Convention in Chicago Today

Business Wire (Apr 24, 2013)
NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9

Business Wire (Apr 22, 2013)
NanoViricides President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics and the California NanoSystems Institute at UCLA

Business Wire (Mar 20, 2013)
NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization, in Rockville, MD tomorrow

Business Wire (Mar 5, 2013)
NanoViricides Announces Retirement of Its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company Reports Having More Than Two Years of Cash on Hand

Business Wire (Feb 27, 2013)
NanoViricides, Inc. Announces that Renovation for its cGMP Clinical Drug Facility has Begun; also Addresses Shareholder Concern - Knows No Reason for the Price Drop Yesterday

Business Wire (Feb 26, 2013)
NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Phase I Clinical Trials of its First Drug Candidate

Business Wire (Feb 19, 2013)
Euphoria From Inhibitex Acquisition Spreads To Other Firms
M. E. Garza • Wed, Jan 11, 2012 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

There are no Focus articles on NNVC.OB.

There are no Transcripts on NNVC.OB.

NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Initial Clinical Trials of Its First Drug Candidate

Business Wire (Wed, 7:00AM)
NanoViricides, Inc. Brings in Experienced Executive as Interim CFO

Business Wire (May 13, 2013)
NanoViricides to Present at the 2013 BIO International Convention in Chicago Today

Business Wire (Apr 24, 2013)
NanoViricides Anticipates FluCide™ Drug Candidates to be Effective Against H7N9

Business Wire (Apr 22, 2013)
NanoViricides President Dr. Diwan Invited to Present a Seminar at the Center for Biological Physics and the California NanoSystems Institute at UCLA

Business Wire (Mar 20, 2013)
NanoViricides to Lead Sessions at the Symposium on Nanomedicines- Roadmap to Commercialization, in Rockville, MD tomorrow

Business Wire (Mar 5, 2013)
NanoViricides Announces Retirement of Its Series C Convertible Preferred Stock Held by Seaside 88, LP - Company Reports Having More Than Two Years of Cash on Hand

Business Wire (Feb 27, 2013)
NanoViricides, Inc. Announces that Renovation for its cGMP Clinical Drug Facility has Begun; also Addresses Shareholder Concern - Knows No Reason for the Price Drop Yesterday

Business Wire (Feb 26, 2013)
NanoViricides, Inc. Files Quarterly Report - Reports a Strong Cash Position Sufficient for Phase I Clinical Trials of its First Drug Candidate

Business Wire (Feb 19, 2013)

NNVC.OB NanoViricides, Inc.